Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis : analysis of pooled data from the randomized trials SOLO 1 and SOLO 2
Cork, Michael J. (University of Sheffield Medical School)
Eckert, Laurent (Sanofi)
Simpson, Eric L. (Oregon Health & Science University)
Armstrong, April W (Keck School of Medicine at USC. University of Southern California)
Barbarot, Sebastien (CHU Hôtel-Dieu)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Girolomoni, Giampiero (University of Verona)
de Bruin-Weller, Marjolein (University Medical Center Utrecht)
Wollenberg, Andreas (Klinikum der Universität München)
Kataoka, Yoko (Osaka Habikino Medical Center)
Remitz, Anita (Helsinki University Central Hospital)
Beissert, Stefan (Technische Universität Dresden)
Mastey, Vera (Regeneron Pharmaceuticals Inc.)
Ardeleanu, Marius (Regeneron Pharmaceuticals Inc.)
Chen, Zhen (Regeneron Pharmaceuticals Inc.)
Gadkari, Abhijit (Regeneron Pharmaceuticals Inc.)
Chao, Jingdong (Regeneron Pharmaceuticals Inc.)
Universitat Autònoma de Barcelona

Date:	2020
Abstract:	Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab significantly improves clinical outcomes, is well tolerated, and approved to treat inadequately controlled moderate-to-severe AD in adults; however, its effect on patient-reported outcomes (PROs) is not fully characterized. To evaluate the impact of dupilumab on patient-reported AD symptoms and QoL. Pooled data were analyzed from two identically designed phase 3 studies, LIBERTY AD SOLO 1 (NCT02277743) and SOLO 2 (NCT02277769), assessing the following PROs: Peak Pruritus Numerical Rating Scale (NRS), Pruritus Categorical Scale, SCORing AD (SCORAD), Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), five-dimension EuroQoL questionnaire (EQ-5D), and patient-assessed disease status and treatment effectiveness. Dupilumab rapidly improved (vs. placebo) Peak Pruritus NRS scores by day 2 (p <. 05), anxiety and depression (HADS), and QoL (DLQI) by week 2, and maintained through week 16 (p <. 0001). At week 16, more dupilumab-treated than placebo-treated patients reported improvement in SCORAD itch and sleep, and no pain/discomfort (EQ-5D) (p <. 0001). Cultural differences of translated PROs. Dupilumab had a significant, positive impact on AD symptoms, including itch, sleep, pain, anxiety and depression, and QoL in adults with moderate-to-severe AD.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Atopic dermatitis ; Dupilumab ; Patient-reported outcomes ; Quality of life
Published in:	Journal of Dermatological Treatment, Vol. 31 Núm. 6 (17 2020) , p. 606-614, ISSN 1471-1753

DOI: 10.1080/09546634.2019.1612836
PMID: 31179791

10 p, 1.5 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles